Company news
Infant Bacterial Therapeutics Ab Class B (OMXSTO:IBT_B) news
Infant Bacterial Therapeutics Ab Class B news releases on 6ix. Latest, May 7, 2026: Annual General Meeting of Infant Bacterial Therapeutics
Press releases & updates
Annual General Meeting of Infant Bacterial Therapeutics
May 7, 2026
IBT_B: Operating loss widened in Q1 2026 as IBP-9414 nears FDA submission and commercialization
May 6, 2026
Correction: Notice of Annual General Meeting of Infant Bacterial Therapeutics
April 2, 2026
Notice of Annual General Meeting of Infant Bacterial Therapeutics
March 30, 2026
Infant Bacterial Therapeutics AB publishes the Annual Report for 2025
March 27, 2026
Infant Bacterial Announces Phase III IBP-9414 Study Results
March 3, 2026
Infant Bacterial Therapeutics Q4 Operating Loss SEK 20.5 Mln
February 6, 2026
Infant Bacterial Therapeutics Secures Partnership For Production Of Drug Product
December 12, 2025
Infant Bacterial Therapeutics Secures Partnership For Production Of Drug Substance
November 20, 2025
Infant Bacterial Therapeutics Q3 Operating Loss SEK 48.5 Mln
November 13, 2025
Infant Bacterial Therapeutics AB: Quarterly Trading Report 2025 Q3
October 3, 2025
IBT_B: FDA review of IBP-9414 progresses as losses narrow and launch preparations intensify
August 20, 2025
IBT_B: FDA Breakthrough Therapy Designation for IBP-9414 accelerates IBT's market path
May 7, 2025
IBT_B: IBP-9414's Phase 3 trial showed 27% lower mortality; BLA submission planned for 2025
February 13, 2025
IBT_B: Phase 3 trial for IBP-9414 cut infant mortality, supporting IBT's regulatory push
November 14, 2024
IBT_B: Significant 27% mortality reduction observed in preterm infants, despite missed primary endpoints
September 3, 2024
IBT_B: Phase 3 trial for IBP-9414 completed; results expected Q3 2024 amid higher H1 losses
August 28, 2024